Skip to content
‹ Back to IndustriesSciences

The Real Space Sweepers

On this new podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration. Astroscale was founded on the principal of wanting to remove debris that is currently in orbit in space, which could become a hazard in the future….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · AstroscaleChris Weeden
Share

Key takeaways

01

On this new podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

Astroscale was founded on the principal of wanting to remove debris that is currently in orbit in space, which could become a hazard in the future….

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On this new podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

Astroscale was founded on the principal of wanting to remove debris that is currently in orbit in space, which could become a hazard in the future.

As a point of pride behind this mission, Astroscale’s team is affectionately nicknamed, “Space Sweepers.” The phrase is used across their organization, from social media to congratulating team members and adding new “Space Sweepers” to their family.

A new film on Netflix is ironically titled “Space Sweepers,” and the hosts of Space to Grow immediately knew that they had to watch it. Would the film live up to their idea? Is the film even really about space?

On this fun bonus segment, Chris Blackerby and Charity Weeden break down the newly released film and judge how accurate the science is behind the fiction.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM for unified engagement

UCB commits to Veeva Vault CRM for unified engagement

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show how quickly a worldwide migration is moving.

Nov 7, 2026

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512